Publications

  • Elizabeth K. Bancroft, Sibel Saya, Elizabeth C. Page, Kathryn Myhill, Sarah Thomas, Jennifer Pope, Anthony Chamberlain, Rachel Hart, Wayne Glover, Jackie Cook, Derek J. Rosario, Brian T. Helfand, Christina Hutten Selkirk, Rosemarie Davidson, Mark Longmuir, Diana M. Eccles, Neus Gadea, Carole Brewer, Julian Barwell, Monica Salinas, Lynn Greenhalgh, Marc Tischkowitz, Alex Henderson, David Gareth Evans, Saundra S. Buys, IMPACT Study Steering Committee, IMPACT Collaborators, Rosalind A. Eeles and Neil K. Aaronson, Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations, British Journal of Urology International, 2018; pp 1-9,  doi:10.1111/bju.14412

 

  • Christos Mikropoulos, Christina G Hutten Selkirk, Sibel Saya, Elizabeth Bancroft, Emily Vertosick, Tokhir Dadaev, Charles Brendler, Elizabeth Page, Alexander Dias, D Gareth Evans, Jeanette Rothwell, Lovise Maehle, Karol Axcrona, Kate Richardson, Diana Eccles, Thomas Jensen, Palle J Osther, Christi J van Asperen, Hans Vasen, Lambertus A Kiemeney, Janneke Ringelberg, Cezary Cybulski, Dominika Wokolorczyk, Rachel Hart, Wayne Glover, Jimmy Lam, Louise Taylor, Monica Salinas, Lidia Feliubadaló, Rogier Oldenburg, Ruben Cremers, Gerald Verhaegh, Wendy A van Zelst-Stams, Jan C Oosterwijk, Jackie Cook, Derek J Rosario, Saundra S Buys, Tom Conner, Susan Domchek, Jacquelyn Powers, Margreet GEM Ausems, Manuel R Teixeira, Sofia Maia, Louise Izatt, Rita Schmutzler, Kerstin Rhiem, William D Foulkes, Talia Boshari, Rosemarie Davidson, Marielle Ruijs, Apollonia TJM Helderman-van den Enden, Lesley Andrews, Lisa Walker, Katie Snape, Alex Henderson, Irene Jobson, Geoffrey J Lindeman, Annelie Liljegren, Marion Harris, Muriel A Adank, Judy Kirk, Amy Taylor, Rachel Susman, Rakefet Chen-Shtoyerman, Nicholas Pachter, Allan Spigelman, Lucy Side, Janez Zgajnar, Josefina Mora, Carole Brewer, Neus Gadea, Angela F Brady, David Gallagher, Theo van Os, Alan Donaldson, Vigdis Stefansdottir, Julian Barwell, Paul A James, Declan Murphy, Eitan Friedman, Nicola Nicolai, Lynn Greenhalgh, Elias Obeid, Vedang Murthy, Lucia Copakova, John McGrath, Soo-Hwang Teo, Sara Strom, Karin Kast, Daniel A Leongamornlert, Anthony Chamberlain, Jenny Pope, Anna C Newlin, Neil Aaronson, Audrey Ardern-Jones, Chris Bangma, Elena Castro, David Dearnaley, Jorunn Eyfjord, Alison Falconer, Christopher S Foster, Henrik Gronberg, Freddie C Hamdy, Oskar Johannsson, Vincent Khoo, Jan Lubinski, Eli Marie Grindedal, Joanne McKinley, Kylie Shackleton, Anita V Mitra, Clare Moynihan, Gad Rennert, Mohnish Suri, Karen Tricker, The IMPACT study collaborators, Sue Moss, Zsofia Kote-Jarai, Andrew Vickers, Hans Lilja, Brian T Helfand & Rosalind A Eeles, Prostate-Specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition, British Journal of Cancer, 2018; pp 1-11, doi:10.1038/bjc.2017.429

 

  • Ruben G.Cremers, Rosalind A.Eeles, Elizabeth K.Bancroft, Janneke Ringelberg-Borsboom, Hans F.Vasen, Christi J. Van Asperen, The IMPACT Steering Committee, Jack A.Schalken, Gerald W.Verhaegh, Lambertus A.Kiemeney, The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers, Urologic Oncology: Seminars and Original Investigations, Volume 33, Issue 5, May 2015, Pages 202.e19-202.e28, ISSN 1078-1439,

 

  • Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón Y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. Eur Urol. 2014; 66(3);489-499.  PMID: 24484606.  Selected as the Best Fundamental Research Paper published in Eur Urol 2014.

 

  • Killick E, , Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators, Kote-Jarai Z, Eeles RA.
    Telomere length shows no association with BRCA1 and BRCA2 mutation status.PLoS One. 2014 Jan 29;9(1) e86659

 

  • Mikropoulos C, Eeles RA  IMPACT Study: Targeted Prostate Cancer Screening. 2013;18(8):e28. doi: 10.1634/theoncologist.2013-0221.

 

  • Castro E, Goh CL, Eeles RA. Prostate cancer screening in BRCA and Lynch syndrome mutation carriers. 
    Am Soc Clin Oncol Educ Book. 2013.

 

  • Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M, Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R, Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M, Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME, Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ, Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z, Eeles, Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.J Clin Oncol. 2013 May 10;31(14):1748-57.

 

  • Castro E. and Eeles R.A. The role of BRCA1and BRCA2 in prostate cancer. Asian J Androl. 2012 May;14(3):409-14.

 

  • Killick E, Morgan R, Launchbury F, Bancroft E, Page E, Castro E, Kote-Jarai Z, Aprikian A, Blanco I, Clowes V, Domchek S, Douglas F, Eccles D, Evans DG, Harris M, Kirk J, Lam J, Lindeman G, Mitchell G, Pachter N, Selkirk C, Tucker K, Zgajnar J, Eeles R, Pandha H. The Role of Engrailed-2 (EN2) as an early prostate cancer detection biomarker in a genetically high risk group of men.Sci Rep. 2013;3:2059

 

  • Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L; IMPACT Study Collaborators, Easton DF, Eeles RA. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study. BJUI (Sept, 2010, 14, doi: 10.1111/j.1464-410X.2010.09648.x.

 

  • Whitaker H, Kote-Jarai Z, Ross-Adams H, Warren A, Burge A, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman G, Evans DG, Blanco I, Mercer S, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Lilja H, Easton D, The IMPACT Study Steering Committee, The IMPACT Study Collaborators, Cooper C, Eeles R, Neal, DThe rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PloS One 2010 Oct 13;5(10)

 

  • Mitra AV, Jameson C, Barbachano Y, Sodha N, Kote-Jarai Z, Javed A, Bancroft E, Fletcher A, Cooper C, Peock S, IMPACT and EMBRACE Collaborators, Easton D, Eeles R, Foster CS, Elevated expression of Ki-67 identifies aggressive prostate cancer but does not Distinguish BRCA1 and BRCA2 mutation carriersOncol Rep. 2010; 23(2):299-305.

 

  • Mitra A, Jameson C, Y. Barbachano, N. Sodha, Z. Kote-Jarai, A. Javed, E. Bancroft, A. Fletcher, Christopher S. Foster, C. Cooper, S. Peock, D. Easton, R. Eeles. Overexpression of TP53 is Associated with Aggressive Prostate Cancer but does not Distinguish Disease in BRCA1 or BRCA2 Mutation Carriers from a Control Group.The Open Prostate Cancer Journal 2009;2:38-45

 

  • Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, Sodha N, Bancroft E, Fletcher A, Cooper C, Easton D; IMPACT Steering Committee and IMPACT and EMBRACE Collaborators, Eeles R, Foster CS. Overexpression of RAD51 occurs in aggressive prostatic cancerHistopathology2009; 55: 696-704.

 

  • Mitra A,Fisher C, Foster CS, Jameson C, Barbachanno Y, Bartlett J, Bancroft E, Doherty R, Kote-Jarai Z, Peock S, Easton D, Eeles Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotypeBritish J Cancer 2008; 98: 502-7

 

  • Mercer C, Eccles D, Mitra A, Bancroft E, Eeles RThe Genetics of Prostate Cancer and the Potential for Targeted Screening: the IMPACT studyOncology News, 2007; Volume 2 Issue 2, August/September.

 

  • Mitra A, Bancroft E, Eeles R, on behalf of the IMPACT Steering committee and collaboratorsA review of targeted screening for prostate cancer: introducing the IMPACT StudyBr J Urol 2007; 99(6); 1350-1355.